Drug General Information (ID: DDIAPIJU97)
Drug Name			Carfilzomib		Drug Info		Von Willebrand Factor Human		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Protease Inhibitors				Coagulation Modifiers

Mechanism of Carfilzomib-Von Willebrand Factor Human Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Carfilzomib				Von Willebrand Factor Human
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Carfilzomib and Von Willebrand Factor Human

Recommended Action
Management		Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis. Thromboprophylaxis should be considered according to local treatment protocols. Close monitoring for thromboembolic events is recommended in patients with known risk factors (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking) for thromboembolism. Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Cerner Multum, Inc. "Australian Product Information.".
3	Product Information. Kyprolis (carfilzomib). Onyx Pharmaceuticals Inc, South San Francisco, CA.